X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Nordic Nanovector gains access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment.
Lead Product(s): Radioimmunoconjugate-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Thor Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 06, 2023
Details:
ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer and sarcoma patients.
Lead Product(s): Sodium Deoxycholate
Therapeutic Area: Oncology Product Name: ATX-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: APIM Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 09, 2022
Details:
Betalutin (177Lu lilotomab satetraxetan), is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) for the treatment of Hodgkin B-cell lymphoma.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Betalutin® (177Lu Lilotomab Satetraxetan), showed signs of efficacy in this frail, elderly and difficult-to-treat patient population, the independent expert panel reported that the efficacy data are less promising than the data reported from the Phase 2a LYMRIT 37-01 trial.
Lead Product(s): 177Lu Lilotomab Satetraxetan,Lilotomab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The primary objective of the PARADIGME trials is to determine the effectiveness of Betalutin (177Lu Lilotomab Satetraxetan), a novel single-dose radioimmunotherapy that targets CD37, an antigen found on the surface of tumour cells of Follicular Lymphoma.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Humalutin® (177Lu-DOTA-NNV003), acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents repair of DNA breaks by blocking activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 (PARP1 and PARP2).
Lead Product(s): 177Lu-DOTA-NNV003,Olaparib
Therapeutic Area: Oncology Product Name: Humalutin
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
106 patients has been enrolled for PARADIGME, ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) for the treatment of anti-CD20 refractory follicular lymphoma.PARADIGME data to be reported in second half of 2022.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Details:
Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmuno conjugate has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ICON Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
